AstraZeneca : to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data - Form 6-K -December 12, 2023 at 06:30 am EST
A4665w FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...